Amedeo Smart

Free Medical Literature Service

 

Amedeo

Chronic Heart Failure
  Free Subscription

Articles published in
Lancet
    August 2025
  1. KOHSAKA S, Heidenreich PA
    Vericiguat across the heart failure spectrum.
    Lancet. 2025 Aug 29:S0140-6736(25)01765-9. doi: 10.1016/S0140-6736(25)01765.
    >> Share

  2. BUTLER J, McMullan CJ, Anstrom KJ, Barash I, et al
    Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.
    Lancet. 2025 Aug 29:S0140-6736(25)01665-4. doi: 10.1016/S0140-6736(25)01665.
    >> Share

  3. ZANNAD F, O'Connor CM, Butler J, McMullan CJ, et al
    Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.
    Lancet. 2025 Aug 29:S0140-6736(25)01682-4. doi: 10.1016/S0140-6736(25)01682.
    >> Share

  4. ROSSELLO X, Prescott EIB, Kristensen AMD, Latini R, et al
    beta blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials.
    Lancet. 2025 Aug 29:S0140-6736(25)01592-2. doi: 10.1016/S0140-6736(25)01592.
    >> Share

  5. ANDERSON CS, Hua C, Wang Z, Wang C, et al
    Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-randomised, controlled trial in China.
    Lancet. 2025 Aug 28:S0140-6736(25)01485-0. doi: 10.1016/S0140-6736(25)01485.
    >> Share

  6. BHATT AS, Vardeny O
    Influenza vaccination in heart failure: a shot worth taking?
    Lancet. 2025 Aug 28:S0140-6736(25)01679-4. doi: 10.1016/S0140-6736(25)01679.
    >> Share

  7. THE LANCET
    Heart failure: time to prioritise prevention.
    Lancet. 2025 Aug 28:S0140-6736(25)01775-1. doi: 10.1016/S0140-6736(25)01775.
    >> Share

  8. KHAN SS, Berwanger O, Fiuzat M, McMurray JJ, et al
    Prioritising the primary prevention of heart failure.
    Lancet. 2025 Aug 28:S0140-6736(25)01393-5. doi: 10.1016/S0140-6736(25)01393.
    >> Share

  9. UDELL JA, Bahit MC, Campbell P, Butler J, et al
    Prevention of heart failure after acute myocardial infarction.
    Lancet. 2025 Aug 28:S0140-6736(25)01394-7. doi: 10.1016/S0140-6736(25)01394.
    >> Share

  10. OSTROMINSKI JW, Cheng AYY, Nelson AJ, Neuen BL, et al
    Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention.
    Lancet. 2025 Aug 28:S0140-6736(25)01384-4. doi: 10.1016/S0140-6736(25)01384.
    >> Share

  11. WALSH M, Collister D, Gallagher M, Mark PB, et al
    Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial.
    Lancet. 2025;406:695-704.
    >> Share

    February 2025
  12. DEANFIELD J
    Effects of semaglutide on heart failure outcomes - Author's reply.
    Lancet. 2025;405:543-544.
    >> Share

  13. HAN J, Shan D
    Effects of semaglutide on heart failure outcomes.
    Lancet. 2025;405:542.
    >> Share

  14. NEVES JS, Packer M, Ferreira JP
    Effects of semaglutide on heart failure outcomes.
    Lancet. 2025;405:542-543.
    >> Share

    August 2024
  15. RUTTEN FH, Groenewegen A
    Mineralocorticoid receptor antagonists for every patient with heart failure.
    Lancet. 2024 Aug 30:S0140-6736(24)01755-0. doi: 10.1016/S0140-6736(24)01755.
    >> Share

  16. JHUND PS, Talebi A, Henderson AD, Claggett BL, et al
    Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis.
    Lancet. 2024 Aug 30:S0140-6736(24)01733-1. doi: 10.1016/S0140-6736(24)01733.
    >> Share

  17. HAGE C
    GLP-1 receptor agonists in heart failure: how far to expand use?
    Lancet. 2024 Aug 29:S0140-6736(24)01763-X. doi: 10.1016/S0140-6736(24)01763.
    >> Share

  18. KOSIBOROD MN, Deanfield J, Pratley R, Borlaug BA, et al
    Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
    Lancet. 2024 Aug 29:S0140-6736(24)01643-X. doi: 10.1016/S0140-6736(24)01643.
    >> Share

  19. DEANFIELD J, Verma S, Scirica BM, Kahn SE, et al
    Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
    Lancet. 2024;404:773-786.
    >> Share

  20. VADUGANATHAN M
    GLP-1 receptor agonists in heart failure.
    Lancet. 2024;404:727-729.
    >> Share

    April 2024
  21. BUTLER J, Shah SJ, Petrie MC, Borlaug BA, et al
    Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
    Lancet. 2024 Apr 4:S0140-6736(24)00469-0. doi: 10.1016/S0140-6736(24)00469.
    >> Share

  22. DONAL E, L'Official G, Istratoaie S
    Semaglutide-a new treatment for obesity-related heart failure with preserved ejection fraction?
    Lancet. 2024 Apr 4:S0140-6736(24)00653-6. doi: 10.1016/S0140-6736(24)00653.
    >> Share

    March 2024
  23. KIKOINE J, Kilani N, Pitta-Gros B, Yerly P, et al
    Remote haemodynamic monitoring in patients with heart failure.
    Lancet. 2024;403:808.
    >> Share

  24. BRUGTS JJ, Aydin D, Clephas PRD, de Boer RA, et al
    Remote haemodynamic monitoring in patients with heart failure - Authors' reply.
    Lancet. 2024;403:808-809.
    >> Share

  25. KOMAMURA K, Iwase M
    Remote haemodynamic monitoring in patients with heart failure.
    Lancet. 2024;403:807-808.
    >> Share

    February 2024
  26. CAMPBELL P, Rutten FH, Lee MM, Hawkins NM, et al
    Heart failure with preserved ejection fraction: everything the clinician needs to know.
    Lancet. 2024 Feb 14:S0140-6736(23)02756-3. doi: 10.1016/S0140-6736(23)02756.
    >> Share

    November 2023
  27. KHAN Y, Verhaeghe N, Devleesschauwer B, Cavillot L, et al
    Impact of the COVID-19 pandemic on delayed care of cardiovascular diseases in Europe: a systematic review.
    Lancet. 2023;402 Suppl 1:S61.
    >> Share

    August 2023
  28. WILKOFF BL, Filippatos G, Leclercq C, Gold MR, et al
    Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure (AdaptResponse): a global, prospective, randomised controlled trial.
    Lancet. 2023 Aug 24:S0140-6736(23)00912-1. doi: 10.1016/S0140-6736(23)00912.
    >> Share

    May 2023
  29. ANGERMANN CE
    Remote pulmonary artery pressure monitoring in heart failure care: part of the new normal?
    Lancet. 2023 May 19:S0140-6736(23)01010-3. doi: 10.1016/S0140-6736(23)01010.
    >> Share

  30. BRUGTS JJ, Radhoe SP, Clephas PRD, Aydin D, et al
    Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial.
    Lancet. 2023 May 19:S0140-6736(23)00923-6. doi: 10.1016/S0140-6736(23)00923.
    >> Share

    April 2023
  31. SCHLAICH MP, Bellet M, Weber MA, Bakris GL, et al
    Fluid retention and heart failure in the PRECISION trial - Authors' reply.
    Lancet. 2023;401:1335-1336.
    >> Share

  32. KOHAN DE, Heerspink HJL
    Fluid retention and heart failure in the PRECISION trial.
    Lancet. 2023;401:1335.
    >> Share

    March 2023
  33. HE J, Ouyang N, Guo X, Sun G, et al
    Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial.
    Lancet. 2023 Mar 2:S0140-6736(22)02603-4. doi: 10.1016/S0140-6736(22)02603.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016